InfuSystem Holdings, Inc (ticker: INFU) is an NYSE-listed clinical biotech company. DredgeCap's structured extraction of INFU's SEC filings surfaces 5 active risk signals, including 4 late-filing signals, and 1 auditor-change signal. INFU reported $33.68M in revenue and $1.02M for the period ending 2026-03-31, with operating cash flow of $970K. Cash and equivalents stood at $2.11M (up 39.8% year-over-year). Total assets of $98.66M exceed total liabilities of $39.91M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
INFU Legal Proceedings
DredgeCap has not located any disclosed legal proceedings for InfuSystem Holdings, Inc (INFU) in the SEC filings currently cached or in the federal-court records searched. 0 periodic filings reviewed, 0 with specific disclosure content. The absence of records here does not certify that the company is free of litigation — coverage reflects only what DredgeCap has cached.